[18F] FBB cortical uptake is not related to the age of onset of Alzheimer’s disease

Abstract

Aim To investigate the relationships between amyloid burden in brain and the age of onset of Alzheimer’s disease. Materials and methods We examined 60 patients with clinical diagnosis of Alzheimer’s disease. Of them, 22 were early-onset of Alzheimer’s disease and 38 were late-onset of Alzheimer’s disease. All of them underwent a brain PET scan 90 minutes after the injection of 4-[(E)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline ([18F] FBB); 300 ± 10 MBq). Relationships between amyloid burden in brain and age of onset of Alzheimer’s disease were assessed by means of statistical parametric mapping version 12. Results There were no significant differences [18F] FBB uptake between early-onset of Alzheimer’s disease and late-onset of Alzheimer’s disease patients. Conclusion In our study group, the age of onset is not related to brain amyloid burden in Alzheimer’s disease patients.

Correlation of [18F]florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach

“…The features extracted from AD patients in the right lateral orbital gyrus of the frontal lobe (a) and in the right anterior orbital gyrus of the frontal lobe (b) exhibit a significant difference with respect to the background estimated from control subjects, as confirmed also by the Student's t-test on the distributions of the two patient categories with respect to a threshold age A (c, d). differences between EOAD and LOAD patients [17]. The results presented here are not in contradiction with previous findings.…”

“…However, EOAD introduces an additional element of complication in the AD landscape. While differences in cerebral metabolic impairment between EAOD and LOAD were observed and also supported by histopathological findings [15,16], suggesting the existence of biological subtypes of AD, the Aβ deposition seems not to be correlated with the age of onset of AD [17].…”

“…The results presented here are not in contradiction with previous findings. While in [17] we made the observations only based on the SUV, here we extended the analysis to the recognition and possible interpretation of patterns. Different metabolic patterns between EOAD and LOAD were identified in the left parietal lobe and in inferior brain regions by using 2-[ 18 F]FDG PET [52,53], contributing to the hypothesis that the regional vulnerability of associative areas of the brain represents a possible signature of EOAD.…”

“…In fact, it was observed that EOAD patients exhibit a higher degree of cortical atrophy and reduced perfusion and metabolism in parietal and lateral temporal cortices with respect to LOAD patients [14,23,24]. Although no evidence regarding the Aβ deposition has been found in these regions [17], it has been not considered until now that the heterogeneity of the accumulation of plaques may present also signs of the structural decline of AD brain and may differ between EOAD and LOAD patients. As a result, a reliable textural indicator of EOAD is currently missing and a texture-based analysis of the difference between EOAD and LOAD patients is not reported in the literature.…”

Recent advances in digital Positron Emission Tomography

“…The precise measurement of the cellular functionality obtained with Positron Emission Tomography (PET) is an indispensable clinical tool, the effectiveness of which has been largely demonstrated. For instance, the reduction of brain activity and the deposition of Amyloid plaques measured with [18F]-FDG and [18F]-FBB PET is used in the clinical practice and is considered a clear indication of the onset of Alzheimer's disease [1].…”